Evaluation and Management of Chronic Heart Failure in Children and Adolescents With Congenital Heart Disease: A Scientific Statement From the American Heart Association

• Published in: Circulation (New York, N.Y.) Vol. 150; no. 2; p. e33
• Main Authors: Amdani, Shahnawaz, Conway, Jennifer, George, Kristen, Martinez, Hugo R, Asante-Korang, Alfred, Goldberg, Caren S, Davies, Ryan R, Miyamoto, Shelley D, Hsu, Daphne T
• Format: Journal Article
• Language: English
• Published: United States 09.07.2024
• Subjects: heart failure; heart disease, congenital; adolescent; diagnosis; ventricular dysfunction; AHA Scientific Statements; child; disease management
• ISSN: 0009-7322; 1524-4539; 1524-4539
• DOI: 10.1161/CIR.0000000000001245

With continued medical and surgical advancements, most children and adolescents with congenital heart disease are expected to survive to adulthood. Chronic heart failure is increasingly being recognized as a major contributor to ongoing morbidity and mortality in this population as it ages, and treatment strategies to prevent and treat heart failure in the pediatric population are needed. In addition to primary myocardial dysfunction, anatomical and pathophysiological abnormalities specific to various congenital heart disease lesions contribute to the development of heart failure and affect potential strategies commonly used to treat adult patients with heart failure. This scientific statement highlights the significant knowledge gaps in understanding the epidemiology, pathophysiology, staging, and outcomes of chronic heart failure in children and adolescents with congenital heart disease not amenable to catheter-based or surgical interventions. Efforts to harmonize the definitions, staging, follow-up, and approach to heart failure in children with congenital heart disease are critical to enable the conduct of rigorous scientific studies to advance our understanding of the actual burden of heart failure in this population and to allow the development of evidence-based heart failure therapies that can improve outcomes for this high-risk cohort.